Pfizer Adds Urgency To Call For Drug Benefit: 107th Congress Is Well-Aligned
Executive Summary
Pfizer is pressing for Congressional action on expanded drug benefits for the elderly in its early meetings with the Republican health committee leaders in the 107th Congress.
You may also be interested in...
Medicare FSS Plan Would Cost VA Over $500 Mil., Rep. Stearns Says
Extending federal supply schedule prices for pharmaceuticals to the Medicare population could cost the Department of Veterans Affairs half a billion dollars annually, Rep. Stearns (R-Fla.) told a House Commerce/Health & Environment Subcommittee hearing on seniors' access to prescription drugs Oct. 4.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials